Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations

Tareq A. Juratli; Pamela S. Jones; Nancy Wang; Megha Subramanian; Simon J.B. Aylwin; Yazmin Odia; Elham Rostami; Olafur Gudjonsson; Brian L. Shaw; Daniel P. Cahill; Evanthia Galanis; Fred G. Barker; Sandro Santagata; Priscilla K. Brastianos

doi:10.1002/cncr.32197

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations

Tareq A. Juratli, Pamela S. Jones, Nancy Wang, Megha Subramanian, Simon J.B. Aylwin, Yazmin Odia, Elham Rostami, Olafur Gudjonsson, Brian L. Shaw, Daniel P. Cahill, Evanthia Galanis, Fred G. Barker, Sandro Santagata, Priscilla K. Brastianos

Medical Oncology

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Original language	English (US)
Pages (from-to)	2910-2914
Number of pages	5
Journal	Cancer
Volume	125
Issue number	17
DOIs	https://doi.org/10.1002/cncr.32197
State	Published - Sep 2019

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/cncr.32197

Cite this

@article{a9ae64f25a964971aeadf988e92c4940,

title = "Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations",

author = "Juratli, {Tareq A.} and Jones, {Pamela S.} and Nancy Wang and Megha Subramanian and Aylwin, {Simon J.B.} and Yazmin Odia and Elham Rostami and Olafur Gudjonsson and Shaw, {Brian L.} and Cahill, {Daniel P.} and Evanthia Galanis and Barker, {Fred G.} and Sandro Santagata and Brastianos, {Priscilla K.}",

note = "Funding Information: Sandro Santagata is supported by the National Institutes of Health (U54CA225088) and the Ludwig Center at Harvard. Priscilla K. Brastianos receives salary support from the National Institutes of Health (1R01CA227156-01), the Breast Cancer Research Foundation, Susan G. Komen, and Damon Runyon Cancer Research. Funding Information: Yazmin Odia reports grants from Bristol-Myers Squibb and grants and other from Novocure outside the submitted work. She also reports advising roles for Novocure and Abbvie. Daniel P. Cahill reports receiving honoraria from Merck and Lilly outside the submitted work. Eva Galanis reports research funding from Bristol-Myers Squibb, Genentech, Merck, and Tracon and personal fees from Celgene, KIYATEC, Tactical Therapeutics, and Oncorus outside the submitted work. Sandro Santagata is a consultant for RareCyte. Priscilla K. Brastianos reports honoraria for consulting from Tesaro, Lilly, Angiochem, and Genentech-Roche; speaker{\textquoteright}s honoraria from Genentech-Roche and Merck; and research funding (to Massachusetts General Hospital) from Merck and Pfizer. The other authors made no disclosures.",

year = "2019",

month = sep,

doi = "10.1002/cncr.32197",

language = "English (US)",

volume = "125",

pages = "2910--2914",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "17",

}

TY - JOUR

T1 - Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations

AU - Juratli, Tareq A.

AU - Jones, Pamela S.

AU - Wang, Nancy

AU - Subramanian, Megha

AU - Aylwin, Simon J.B.

AU - Odia, Yazmin

AU - Rostami, Elham

AU - Gudjonsson, Olafur

AU - Shaw, Brian L.

AU - Cahill, Daniel P.

AU - Galanis, Evanthia

AU - Barker, Fred G.

AU - Santagata, Sandro

AU - Brastianos, Priscilla K.

N1 - Funding Information: Sandro Santagata is supported by the National Institutes of Health (U54CA225088) and the Ludwig Center at Harvard. Priscilla K. Brastianos receives salary support from the National Institutes of Health (1R01CA227156-01), the Breast Cancer Research Foundation, Susan G. Komen, and Damon Runyon Cancer Research. Funding Information: Yazmin Odia reports grants from Bristol-Myers Squibb and grants and other from Novocure outside the submitted work. She also reports advising roles for Novocure and Abbvie. Daniel P. Cahill reports receiving honoraria from Merck and Lilly outside the submitted work. Eva Galanis reports research funding from Bristol-Myers Squibb, Genentech, Merck, and Tracon and personal fees from Celgene, KIYATEC, Tactical Therapeutics, and Oncorus outside the submitted work. Sandro Santagata is a consultant for RareCyte. Priscilla K. Brastianos reports honoraria for consulting from Tesaro, Lilly, Angiochem, and Genentech-Roche; speaker’s honoraria from Genentech-Roche and Merck; and research funding (to Massachusetts General Hospital) from Merck and Pfizer. The other authors made no disclosures.

PY - 2019/9

Y1 - 2019/9

UR - http://www.scopus.com/inward/record.url?scp=85069920445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069920445&partnerID=8YFLogxK

U2 - 10.1002/cncr.32197

DO - 10.1002/cncr.32197

M3 - Article

C2 - 31314136

AN - SCOPUS:85069920445

SN - 0008-543X

VL - 125

SP - 2910

EP - 2914

JO - Cancer

JF - Cancer

IS - 17

ER -

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this